News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
147,360 Results
Type
Article (4669)
Company Profile (6)
Press Release (142685)
Multimedia
Podcasts (8)
Webinars (4)
Section
Business (48715)
Career Advice (62)
Deals (8199)
Drug Delivery (16)
Drug Development (16372)
Employer Resources (4)
FDA (3947)
Job Trends (2492)
News (73173)
Policy (8838)
Tag
2027 BioCapital Standard (1)
2027 Biotech Bay Standard (1)
2027 Genetown Standard (1)
40 Under 40 (1)
Academia (302)
Accelerated approval (14)
ADA (7)
Allergies (59)
Alliances (12923)
ALS (81)
Alzheimer's disease (329)
Antibody-drug conjugate (ADC) (199)
Approvals (4370)
Artificial intelligence (88)
ASCO (60)
Autoimmune disease (71)
Automation (8)
Bankruptcy (51)
Belgium (5)
Best Places to Work (2132)
BIO (10)
Biologics (14)
BIOSECURE Act (1)
Biosimilars (162)
BioSpace Insights (5)
Biotechnology (10)
Bispecific (10)
Bladder cancer (72)
Brain cancer (25)
Breast cancer (131)
Cancer (1420)
Cardiovascular disease (102)
Career advice (61)
Career pathing (1)
CAR-T (31)
CDC (5)
CDMO (16)
Celiac Disease (1)
Cell therapy (123)
Cervical cancer (14)
Clinical research (15496)
Collaboration (569)
Commercialization (17)
Compensation (62)
Complete response letters (13)
COVID-19 (574)
CRISPR (14)
C-suite (231)
Cystic fibrosis (31)
Data (1905)
Depression (33)
Dermatology (44)
Diabetes (119)
Diagnostics (1189)
Digital health (19)
Drug discovery (74)
Drug pricing (45)
Drug shortages (5)
Duchenne muscular dystrophy (87)
Earnings (20024)
Editorial (3)
Employer branding (1)
Employer resources (4)
ESMO (76)
Events (16757)
Executive appointments (189)
Eye disease (1)
FDA (5051)
Fibrodysplasia Ossificans Progressiva (2)
Fragile X (1)
Friedreich's ataxia (7)
Frontotemporal dementia (8)
Funding (355)
Gene editing (25)
Generative AI (7)
Gene therapy (91)
GLP-1 (220)
Government (1761)
Grass and pollen (3)
Guidances (100)
Healthcare (3020)
Hematology (24)
HIV (33)
Huntington's disease (10)
Idiopathic pulmonary fibrosis (3)
IgA nephropathy (33)
Immunology and inflammation (24)
Immuno-oncology (29)
Indications (74)
Infectious disease (666)
Inflammatory bowel disease (69)
Inflation Reduction Act (2)
Influenza (37)
Intellectual property (91)
Interviews (8)
IPO (3479)
IRA (12)
Job creations (504)
Job search strategy (59)
JPM (3)
Kidney cancer (8)
Kidney disease (29)
Labor market (4)
Layoffs (36)
Leadership (1)
Legal (1554)
Licensing (29)
Liver cancer (34)
Longevity (4)
Lung cancer (249)
Lung diease (4)
Lymphoma (105)
Machine learning (6)
Management (1)
Manufacturing (255)
Marketing (10)
MASH (43)
Medical affairs (1)
Medical device (2802)
Medtech (2840)
Mergers & acquisitions (5016)
Metabolic disorders (289)
mRNA (43)
Multiple sclerosis (56)
NASH (7)
Netherlands (5)
Neurodegenerative disease (66)
Neuropsychiatric disorders (15)
Neuroscience (692)
NextGen: Class of 2026 (625)
Non-profit (548)
Now hiring (1)
Obesity (125)
Opinion (17)
Ovarian cancer (76)
Pain (46)
Pancreatic cancer (50)
Parkinson's disease (68)
Partnered (5)
Patents (176)
Patient recruitment (179)
Patient selection (27)
Peanut (13)
People (10178)
Peptides (4)
Pharmaceutical (3)
Pharmacy benefit managers (9)
Phase 1 (3674)
Phase 2 (6337)
Phase 3 (6453)
Pipeline (3075)
Policy (39)
Postmarket research (608)
Preclinical (1249)
Press Release (4)
Prostate cancer (84)
Psychedelics (4)
Radiopharmaceuticals (85)
Rare diseases (219)
Real estate (1031)
Recruiting (3)
Regenerative medicine (5)
Regulatory (7159)
Reports (23)
Research institute (314)
Resumes & cover letters (4)
Rett syndrome (9)
RNA editing (5)
RSV (25)
Schizophrenia (55)
Series A (64)
Series B (47)
Service/supplier (3)
Sickle cell disease (16)
Special edition (2)
Spinal muscular atrophy (16)
Sponsored (4)
Startups (652)
Stomach cancer (3)
Substance use disorders (5)
Supply chain (27)
Switzerland (5)
Tariffs (15)
The Weekly (8)
Vaccines (233)
Venture capital (15)
Weight loss (77)
Women's health (27)
Worklife (2)
Date
Today (40)
Last 7 days (164)
Last 30 days (544)
Last 365 days (5721)
2026 (4772)
2025 (5407)
2024 (6504)
2023 (7706)
2022 (14132)
2021 (14339)
2020 (12925)
2019 (9103)
2018 (7178)
2017 (7144)
2016 (6300)
2015 (7536)
2014 (5642)
2013 (4605)
2012 (4831)
2011 (4895)
2010 (4643)
Location
Africa (166)
Alabama (7)
Alaska (1)
Arizona (64)
Arkansas (1)
Asia (23988)
Australia (3173)
California (1753)
Canada (2575)
China (659)
Colorado (27)
Connecticut (90)
Delaware (47)
Europe (22739)
Florida (291)
Georgia (66)
Hawaii (2)
Idaho (6)
Illinois (133)
India (78)
Indiana (159)
Iowa (9)
Japan (435)
Kansas (10)
Kentucky (1)
Louisiana (11)
Maine (10)
Maryland (269)
Massachusetts (1589)
Michigan (35)
Minnesota (81)
Missouri (33)
Montana (1)
Nebraska (3)
Nevada (30)
New Hampshire (14)
New Jersey (1157)
New York (606)
North Carolina (242)
North Dakota (1)
Northern California (773)
Ohio (41)
Oklahoma (1)
Oregon (7)
Pennsylvania (392)
Puerto Rico (1)
Rhode Island (3)
South America (224)
South Carolina (2)
Southern California (853)
Tennessee (13)
Texas (243)
United States (7498)
Utah (46)
Vermont (2)
Virginia (83)
Washington D.C. (5)
Washington State (128)
Wisconsin (9)
Wyoming (1)
147,360 Results for "boehringer ingelheim canada ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’
Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.
August 24, 2026
·
1 min read
·
Tristan Manalac
Cancer
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including multi-specific antibodies, antibody-drug conjugates and T cell engagers.
September 22, 2026
·
2 min read
·
Tristan Manalac
Press Releases
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies
· New research team expands capabilities at Boehringer’s U.S. R&D site in Ridgefield, Connecticut.
July 9, 2026
·
1 min read
Press Releases
Boehringer Ingelheim Canada extends global ‘Detect the SOS’ mission to address the uACR testing gap that leaves millions of Canadian patients vulnerable to undetected heart and kidney risks
September 29, 2026
·
4 min read
Press Releases
Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development
October 22, 2026
·
4 min read
Press Releases
AimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107
October 26, 2026
·
2 min read
Press Releases
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
August 13, 2026
·
9 min read
Press Releases
Boehringer Ingelheim Spotlights Next Generation of Veterinary Researchers
August 10, 2026
·
5 min read
Press Releases
Boehringer Ingelheim Establishes Metabolic Matters Steering Committee to Advance More Connected Care for Obesity and Related Liver Diseases
October 28, 2026
·
5 min read
Obesity
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors.
October 1, 2026
·
2 min read
·
Heather McKenzie
1 of 14,736
Next
